secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-05-26T12:48:49+00:00
Accession:  0001178913-26-002900
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics announces 1-for-10 reverse share split to maintain Nasdaq listing
--------------------------------------------------------------------------------

- Reverse share split at 1:10 ratio; effective after market close May 28, 2026; split-adjusted trading begins May 29, 2026.
- Ticker remains SLXN; new CUSIP assigned; par value increases from $0.0135 to $0.135 per share.
- No fractional shares issued; DTC participants' fractional shares rounded up to nearest whole share.
- Split intended to maintain Nasdaq minimum bid price compliance (Rule 5550(a)(2)) and support equity financings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002900/0001178913-26-002900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002900/zk2635400.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer